{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:37:05Z","timestamp":1792143425684,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for\n                      <jats:sup>225<\/jats:sup>\n                      Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of\n                      <jats:sup>225<\/jats:sup>\n                      Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Radiochemistry and animal studies were favorable. Thirty-two patients received\n                      <jats:sup>225<\/jats:sup>\n                      Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq\/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq\/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of\n                      <jats:sup>225<\/jats:sup>\n                      Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.23.00573","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T16:00:30Z","timestamp":1699027230000},"page":"842-851","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":71,"title":["Prostate-Specific Membrane Antigen\u2013Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of\n                    <sup>225<\/sup>\n                    Ac-J591"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03276572","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-8587","authenticated-orcid":false,"given":"Scott T.","family":"Tagawa","sequence":"first","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-0090","authenticated-orcid":false,"given":"Charlene","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-7343","authenticated-orcid":false,"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-2445","authenticated-orcid":false,"given":"Judith","family":"Stangl-Kremser","sequence":"additional","affiliation":[{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahelia","family":"Bissassar","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Vallabhajosula","sequence":"additional","affiliation":[{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-8744","authenticated-orcid":false,"given":"Sandra Huicochea","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"},{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-4171","authenticated-orcid":false,"given":"Jones T.","family":"Nauseef","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-2627","authenticated-orcid":false,"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-0357","authenticated-orcid":false,"given":"Karla","family":"Ballman","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"},{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0232-5960","authenticated-orcid":false,"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"},{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Bander","sequence":"additional","affiliation":[{"name":"Department of Urology, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0121-2"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"b5","first-page":"81","volume":"3","author":"Silver DA","year":"1997","journal-title":"Clin Cancer Res"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106383108"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091655.77601.0c"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.154"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0231"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32072"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0552"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3696"},{"key":"b19","first-page":"3629","volume":"57","author":"Liu H","year":"1997","journal-title":"Cancer Res"},{"key":"b20","first-page":"6095","volume":"60","author":"McDevitt MR","year":"2000","journal-title":"Cancer Res"},{"key":"b21","first-page":"2008","volume":"61","author":"Ballangrud AM","year":"2001","journal-title":"Cancer Res"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064126"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4167-0"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2019.02.003"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262543"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00539-6"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT143"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2830-7"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24104"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.00573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T18:01:22Z","timestamp":1709056882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.00573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,3,1]]}},"alternative-id":["10.1200\/JCO.23.00573"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.00573","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"2023-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}